Latest Intellectual Property News

Scalare Partners has acquired Fishburners, Australia’s largest startup community, to deepen its founder network and expand integrated support services across the country.

Simble Solutions has launched a strategic collaboration with Macquarie University to accelerate development of its exclusive zinc oxide nanosensor technology, targeting e-skin applications and integration into its IoT platforms.

Legacy Minerals has locked in a farm-in deal with Aurelia Metals for its Cobar Project, allowing Aurelia to earn up to 90% by funding exploration. This partnership leverages Aurelia's established Cobar Basin operations while Legacy focuses on its flagship Mt Carrington project.

A US court has dismissed Identitii's patent infringement claim against JPMorgan Chase, citing patent ineligibility. Identitii plans to appeal, while its core business remains unaffected.

Amplia Therapeutics reported encouraging mature data from its ACCENT pancreatic cancer trial showing improved survival and response rates with narmafotinib. The company raised $27.5 million to fund development and manufacturing scale-up, while discontinuing a parallel trial due to chemotherapy toxicity.

Booster Innovation Fund has trimmed its net asset value per unit to $1.47 following a $723,000 valuation adjustment driven by slower growth and capital raising dynamics in its portfolio.

Advanced Energy Minerals (ASX:AEM) is ramping up its Cap-Chat high purity alumina production, targeting 3,000 tpa by mid-2026 and planning to double capacity to 6,000 tpa by 2029 amid a forecast supply deficit and surging demand.

Critical Resources Limited showcased its diversified critical metals portfolio and advanced battery tech at its 2026 AGM, spotlighting growth prospects in lithium, gold, and base metals across Australia, Canada, and New Zealand.

Racura Oncology has locked in an underwriting agreement covering nearly 1.84 million expiring options, ensuring up to $2.3 million in fresh capital to back its cancer drug development programs.

Tetratherix Limited secures $15 million via institutional placement plus a capped $2 million share purchase plan at a 14% discount, aiming to fast-track manufacturing expansion and commercial partnerships.

Recce Pharmaceuticals has signed a non-binding term sheet with a major Middle Eastern pharma player for exclusive rights to commercialise its R327 Topical Gel across the MENA region, targeting a high diabetes burden market.

Biome Australia has launched a multi-centre clinical trial for its proprietary probiotic BMB18, adding a prestigious Greek university to its research network and commencing recruitment within the expected timeline.